Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer
NCT ID: NCT02820857
Last Updated: 2025-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
153 participants
INTERVENTIONAL
2017-09-04
2024-08-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Recent data on the initial presentation of GEP-NEC have been reported in two retrospective studies and a French cohort study. No standard second-line treatment has been defined for NECs. Despite a very negative prognosis, these NECs have a certain amount of chemosensitivity, close to that of bronchial NECs. Multiple-drug therapies such as Folfiri, or Folfox, or single drug treatments such as temozolomide are the proposed options but with a low level of proof Bevacizumab associated with a cytotoxic chemotherapy has shown promising results in well differentiated neuroendocrine tumors (NET), known for being hypervascular. The efficacy of bevacizumab has also been suggested in patients with NEC, but never in the context of a phase II study. Its combination with Folfiri is efficient and well tolerated in metastatic colorectal cancer. The combination Folfiri-bevacizumab potentially represents an optimized treatment compared to chemotherapy with only Folfiri. No phase II or III studies have reported results for these patients, and no on-going phase II or III trial have been identified to date.
The main objective of this study is to show that, after the failure of a first-line chemotherapy using platinum-etoposide, the combination Folfiri-bevacizumab allows significant prolongation of overall survival in adult patients with GEP-NEC.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
NCT00390416
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
NCT00737438
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
NCT03591731
Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
NCT06504615
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
NCT01928290
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Folfiri-bevacizumab
Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
Folfiri-bevacizumab
Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
Folfiri
Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
Folfiri
Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Folfiri-bevacizumab
Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
Folfiri
Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Poorly differentiated neuroendocrine carcinoma (NEC) from a gastrointestinal tract (from esophagus to anal canal) and biliopancreatic primary or an unknown primary cancer, locally advanced and/or metastatic,
* Centralized review of the diagnostic by a consulting pathologist specializing in NET (TENPATH network),
* Recommendation of a second-line chemotherapy after progression, documented using the RECIST criteria v.1.1, and after a first-line chemotherapy treatment by cisplatin (or carboplatin) + etoposide or in the event of progression in the 6 months following the discontinuation of this first-line treatment,
* Recommendation of a second-line chemotherapy for the refractory patient or contraindicated for platinum-etoposide chemotherapy
* Patients presenting at least one measurable target lesion according to the RECIST criteria v.1.1, in an area not previously irradiated,
* General condition ≤ 2 (WHO),
* Patient of child bearing age accepting to use an effective contraception during treatment and until 6 months after the last administration,
* Patient who signed the informed consent form.
Exclusion Criteria
* Well differentiated neuroendocrine tumor
* Mixed tumor, except if the NEC component is \> 70%, the patient is eligible,
* First-line chemotherapy other than cisplatin (or carboplatin) and etoposide,
* All malignant disease in the three years before randomization, with the exception of basal cell carcinoma or in situ cancer treated for curative purposes,
* A pregnant or breastfeeding woman,
* Lack of efficient contraception (for men or women of reproductive age),
* All medical, geographical, social, and psychological conditions or a legal situation that will not allow the patient to finish the study or sign an informed consent form,
2. Relating to the chemotherapy (Folfiri):
* Any of the following uncontrolled progressive diseases in the 6 months before randomization: liver failure, renal insufficiency, respiratory distress, congestive heart failure (NYHA III-IV), unstable angina, myocardial infarction, significant arrhythmia,
* Known deficiency in dihydropyrimidine dehydrogenase,
* Known Gilbert's syndrome,
* Total bilirubin level \>1.5x the upper limit of normal (ULN); AST (Aspartate transaminase) and/or ALT (Alanine transaminase) \>5x ULN; TP \<50%;
* Neutrophils \<1.5x109/l, platelets \<100x109/l, hemoglobin \<9 g/dl,
* Chronic uncontrolled diarrhea, unresolved intestinal occlusion or subocclusion,
* History of anaphylactic reaction or known intolerance to atropine (sulfate) or to loperamide or to antiemetics administered in association with Folfiri,
* All treatment with concomitant anticonvulsive agents, CYP3A4 inducers (phenytoin, phenobarbital, carbamazepine), discontinued for at least 7 days,
3. Relating to bevacizumab:
* Uncontrolled brain metastases (by local treatment),
* All uncontrolled progressive disease within 1 month prior to randomization: grade 3-4 gastrointestinal bleeding (peptic ulcer, erosive esophagitis or gastritis), infectious disease or intestinal inflammation, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event,
* Uncontrolled high blood pressure defined as a systolic blood pressure \>140 mmHg or diastolic pressure \>90 mmHg,
* Patients receiving anticoagulant treatment with an unstable dose of a vitamin K antagonist treatment, and/or having an abnormal INR (\>3) in the four weeks before the randomization,
* Verified proteinuria above or equal to 1g/24 hours measured from 24 hours of urine if the urinary protein dipstick control is above or equal to 2+,
* Creatinine clearance (MDRD) \<50 ml/min.
* Hypersensitivity to the active substance or to any of the excipients.
* Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service d'Hépato-Gastroenterologie et Oncologie Digestive, Hôpital Sud, CHU d'Amiens
Amiens, , France
Service d'Hépatogastroentérologie, CHU d'Angers
Angers, , France
Service d'Oncologie et Radiothérapie, Institut Sainte Catherine
Avignon, , France
Service de Gastroentérologie et Oncologie Digestive, Hôpital Avicenne
Bobigny, , France
Service de Gastroentérologie et Pancréatologie, Hôpital Beaujon, APHP
Clichy, , France
Service de Gastroentérologie, CHU Henri Mondor
Créteil, , France
Service d'Hépato-Gastroentérologie et Oncologie Digestive, CHU de Dijon
Dijon, , France
Service d'Hépatogastroentéologie, Hôpital Michallon, CHU de Grenoble
Grenoble, , France
Département de Cancérologie Urologique et Digestive, Centre Oscar Lambret
Lille, , France
Département de cancérologie médicale - Groupe des tumeurs endocrines, Centre Léon Bérard
Lyon, , France
Service d'Oncologie Médicale - Hôpital Edouard Herriot - Hospices Civils de Lyon
Lyon, , France
Département d'Oncologie Médicale, Institut Paoli Calmettes
Marseille, , France
Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Hôpital de la Timone, APHM
Marseille, , France
Service d'Oncologie Médicale, Hôpital Saint Eloi, CHU de Montpellier
Montpellier, , France
Service d'Hépatogastroentérologie, CHR d'Orléans
Orléans, , France
Département d'Oncologie Médicale, Hôpital Saint-Antoine
Paris, , France
Service de Gastroentérologie, Hôpital Cochin, APHP
Paris, , France
Service d'Hépato-Gastroenterologie et Oncologie Digestive, Hôpital Européen Georges Pompidou, APHP
Paris, , France
Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Hôpital Haut Lévêque, CHU Bordeaux
Pessac, , France
Pôle Régional de Cancérologie, CHU de Poitiers
Poitiers, , France
Service d'Hépato-Gastroentérologie et Cancérologie, Hôpital Robert Debré, CHU de Reims
Reims, , France
Service d'Hépatogastroentérologie, Hôpital Pontchaillou, CHU de Rennes
Rennes, , France
Service de Gastroentérologie, CHU de Rouen
Rouen, , France
Service de Gastro-Entérologie, Hôpital Nord, CHU de ST-Etienne
Saint-Priest-en-Jarez, , France
Service d'Oncologie Médicale, Hôpital Civil, CHU de Strasbourg
Strasbourg, , France
Service d'Oncologie Endocrinienne, Institut Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Walter T, Lievre A, Coriat R, Malka D, Elhajbi F, Di Fiore F, Hentic O, Smith D, Hautefeuille V, Roquin G, Perrier M, Dahan L, Granger V, Sobhani I, Mineur L, Niccoli P, Assenat E, Scoazec JY, Le Malicot K, Lepage C, Lombard-Bohas C. Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial. Lancet Oncol. 2023 Mar;24(3):297-306. doi: 10.1016/S1470-2045(23)00001-3. Epub 2023 Feb 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-001305-16
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
69HCL14_0442
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.